These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36878564)

  • 41. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
    Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
    Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The changing view of high-grade serous ovarian cancer.
    Berns EM; Bowtell DD
    Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
    Vang R; Shih IeM; Kurman RJ
    Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.
    Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
    Lai J; Tong C; Chien JR
    Anticancer Res; 2021 Sep; 41(9):4417-4422. PubMed ID: 34475063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
    Oswald AJ; Gourley C
    Curr Opin Oncol; 2015 Sep; 27(5):412-9. PubMed ID: 26241347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
    Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
    Farley J; Brady WE; Vathipadiekal V; Lankes HA; Coleman R; Morgan MA; Mannel R; Yamada SD; Mutch D; Rodgers WH; Birrer M; Gershenson DM
    Lancet Oncol; 2013 Feb; 14(2):134-40. PubMed ID: 23261356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
    Shanta K; Nakayama K; Hossain MM; Razia S; Ishibashi T; Ishikawa M; Yamashita H; Kanno K; Sato S; Nakayama S; Otsuki Y; Kyo S
    Curr Oncol; 2022 Jun; 29(6):4020-4033. PubMed ID: 35735430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
    Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
    Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
    Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
    Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in precision therapy of low-grade serous ovarian cancer: A review.
    Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
    Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.